Compare BIIB & CINF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIIB | CINF |
|---|---|---|
| Founded | 1978 | 1950 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 25.2B |
| IPO Year | 1991 | N/A |
| Metric | BIIB | CINF |
|---|---|---|
| Price | $172.50 | $165.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 3 |
| Target Price | $177.40 | ★ $180.33 |
| AVG Volume (30 Days) | ★ 2.0M | 518.0K |
| Earning Date | 10-30-2025 | 10-27-2025 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | ★ N/A | N/A |
| EPS | 10.97 | ★ 13.44 |
| Revenue | $10,065,900,000.00 | ★ $12,078,000,000.00 |
| Revenue This Year | $3.61 | $10.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.86 | ★ $12.34 |
| Revenue Growth | ★ 4.77 | N/A |
| 52 Week Low | $110.04 | $123.02 |
| 52 Week High | $185.17 | $169.86 |
| Indicator | BIIB | CINF |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 56.44 |
| Support Level | $169.24 | $161.04 |
| Resistance Level | $175.94 | $169.86 |
| Average True Range (ATR) | 4.93 | 2.58 |
| MACD | -1.78 | -0.03 |
| Stochastic Oscillator | 18.10 | 55.40 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The company operates in segments: Commercial lines insurance, Personal lines insurance, and Excess and surplus lines insurance, Life insurance, and Investments. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.